Skip to main content

Advertisement

SpringerLink
Log in

Readiness to quit as a predictor for outcomes of smoking-reduction programme with transdermal nicotine patch or bupropion in a sample of 308 patients with schizophrenia

  • Original Paper
  • Published:
European Archives of Psychiatry and Clinical Neuroscience Aims and scope Submit manuscript

Abstract

Readiness to quit has been found to predict smoking-cessation outcomes in a general population. However, little is known about the relationship between the readiness to quit and smoking-reduction outcomes in patients with schizophrenia treated with pharmacological adjuvants. The aim of this study was to examine the association between readiness to quit and smoking-reduction outcomes in patients with schizophrenia. A total of 308 subjects using nicotine replacement therapy (NRT) (N = 242) or bupropion (N = 66) participated in an 8-week smoking-reduction programme. Participants were categorised into precontemplators (N = 127), contemplators (N = 76) and preparators (N = 105) to quit smoking based on the transtheoretical model. There was a significant difference in change in number of cigarettes (NOC) (p = 0.007) and Fagerstrom test for nicotine dependence (FTND) score (nicotine dependence level) (p = 0.029) across the stages of change. A linear regression model revealed trend of increasing reduction in NOC and FTND scores in different stages of change (NOC: B = −1.22, t = −2.81, p = 0.005; FTND: B = −0.43, t = −2.57, p = 0.011). However, the 7-day point prevalence of abstinence was 5.5 % (18/308), but there was no significant association between stage of change and smoking cessation (p = 0.26), possibly due to a very small sample size of successful quitters. In summary, among a cohort of institutionalised chronic schizophrenia patients receiving 8-week NRT or bupropion, stage of change can predict smoking reduction and may serve as a useful indicator for patients’ preparedness before a trial of smoking reduction.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lyon ER (1999) A review of the effects of nicotine on schizophrenia and antipsychotic medications. Psychiatr Serv 50(10):1346–1350

    Article  CAS  PubMed  Google Scholar 

  2. Beratis S, Katrivanou A, Gourzis P (2001) Factors affecting smoking in schizophrenia. Compr Psychiatry 42(5):393–402

    Article  CAS  PubMed  Google Scholar 

  3. Leonard S, Adler LE, Benhammou K, Berger R, Breese CR, Drebing C, Gault J, Lee MJ, Logel J, Olincy A, Ross RG, Stevens K, Sullivan B, Vianzon R, Virnich DE, Waldo M, Walton K, Freedman R (2001) Smoking and mental illness. Pharmacol Biochem Behav 70(4):561–570

    Article  CAS  PubMed  Google Scholar 

  4. Corrigall WA (1991) Understanding brain mechanisms in nicotine reinforcement. Br J Addict 86(5):507–510

    Article  CAS  PubMed  Google Scholar 

  5. Silagy C, Mant D, Fowler G, Lancaster T (2000) Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2

  6. Baker A, Richmond R, Haile M, Lewin TJ, Carr VJ, Taylor RL, Jansons S, Wilhelm K (2006) A randomized controlled trial of a smoking cessation intervention among people with a psychotic disorder. Am J Psychiatry 163(11):1934–1942

    Article  PubMed  Google Scholar 

  7. George TP, Ziedonis DM, Feingold A, Pepper WT, Satterburg CA, Winkel J, Rounsaville BJ, Kosten TR (2000) Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am J Psychiatry 157(11):1835–1842

    Article  CAS  PubMed  Google Scholar 

  8. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, Smith SS, Muramoto ML, Daughton DM, Doan K, Fiore MC, Baker TB (1999) A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 340(9):685–691

    Article  CAS  PubMed  Google Scholar 

  9. Evins AE, Cather C, Rigotti NA, Freudenreich O, Henderson DC, Olm-Shipman CM, Goff DC (2004) Two-year follow-up of a smoking cessation trial in patients with schizophrenia: increased rates of smoking cessation and reduction. J Clin Psychiatry 65(3):307–311

    Article  PubMed  Google Scholar 

  10. Lucksted A, Dixon LB, Sembly JB (2000) A focus group pilot study of tobacco smoking among psychosocial rehabilitation clients. Psychiatr Serv 51(12):1544–1548

    Article  CAS  PubMed  Google Scholar 

  11. Ziedonis DM, George TP (1997) Schizophrenia and nicotine use: report of a pilot smoking cessation program and review of neurobiological and clinical issues. Schizophr Bull 23(2):247–254

    Article  CAS  PubMed  Google Scholar 

  12. Addington J, El-Guebaly N, Campbell W, Hodgins DC, Addington D (1998) Smoking cessation treatment for patients with schizophrenia. Am J Psychiatry 155(7):974–976

    Article  CAS  PubMed  Google Scholar 

  13. Chou KR, Chen R, Lee JF, Ku CH, Lu RB (2004) The effectiveness of nicotine-patch therapy for smoking cessation in patients with schizophrenia. Int J Nurs Stud 41(3):321–330

    Article  PubMed  Google Scholar 

  14. George TP, Vessicchio JC, Sacco KA, Weinberger AH, Dudas MM, Allen TM, Creeden CL, Potenza MN, Feingold A, Jatlow PI (2008) A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia. Biol Psychiatry 63(11):1092–1096

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. Prochaska JO, DiClemente CC (1983) Stages and processes of self-change of smoking: toward an integrative model of change. J Consult Clin Psychol 51(3):390–395

    Article  CAS  PubMed  Google Scholar 

  16. DiClemente CC, Prochaska JO, Fairhurst SK, Velicer WF, Velasquez MM, Rossi JS (1991) The process of smoking cessation: an analysis of precontemplation, contemplation, and preparation stages of change. J Consult Clin Psychol 59(2):295–304

    Article  CAS  PubMed  Google Scholar 

  17. Velicer WF, Norman GJ, Fava JL, Prochaska JO (1999) Testing 40 predictions from the transtheoretical model. Addict Behav 24(4):455–469

    Article  CAS  PubMed  Google Scholar 

  18. Sutton S (2001) Back to the drawing board? A review of applications of the transtheoretical model to substance use. Addiction 96(1):175–186

    Article  CAS  PubMed  Google Scholar 

  19. Strecher VJ, Shiffman S, West R (2005) Randomized controlled trial of a web-based computer-tailored smoking cessation program as a supplement to nicotine patch therapy. Addiction 100(5):682–688

    Article  PubMed  Google Scholar 

  20. Prochaska JO, DiClemente CC, Norcross JC (1992) In search of how people change. Applications to addictive behaviors. Am Psychol 47(9):1102–1114

    Article  CAS  PubMed  Google Scholar 

  21. Abrams DB, Herzog TA, Emmons KM, Linnan L (2000) Stages of change versus addiction: a replication and extension. Nicotine Tob Res 2(3):223–229

    Article  CAS  PubMed  Google Scholar 

  22. Dino G, Kamal K, Horn K, Kalsekar I, Fernandes A (2004) Stage of change and smoking cessation outcomes among adolescents. Addict Behav 29(5):935–940

    Article  PubMed  Google Scholar 

  23. Perz C, DiClemente C, Carbonari J (1996) Doing the right thing at the right time? The interaction of stages and processes of change in successful smoking cessation. Health Psychol 15(6):462–468

    Article  CAS  PubMed  Google Scholar 

  24. Bolliger CT (2000) Practical experiences in smoking reduction and cessation. Addiction 95(1):S19–S24

    Article  PubMed  Google Scholar 

  25. Hughes JR, Carpenter MJ (2005) The feasibility of smoking reduction: an update. Addiction 100(8):1074–1089

    Article  PubMed Central  PubMed  Google Scholar 

  26. Bolliger CT, Zellweger JP, Danielsson T, van Biljon X, Robidou A, Westin A, Perruchoud AP, Sawe U (2002) Influence of long-term smoking reduction on health risk markers and quality of life. Nicotine Tob Res 4(4):433–439

    Article  CAS  PubMed  Google Scholar 

  27. Falba T, Jofre-Bonet M, Busch S, Duchovny N, Sindelar J (2004) Reduction of quantity smoked predicts future cessation among older smokers. Addiction 99(1):93–102

    Article  PubMed  Google Scholar 

  28. Etter M, Mohr S, Garin C, Etter JF (2004) Stages of change in smokers with schizophrenia or schizoaffective disorder and in the general population. Schizophr Bull 30(2):459–468

    Article  PubMed  Google Scholar 

  29. Esterberg ML, Compton MT (2005) Smoking behavior in persons with a schizophrenia-spectrum disorder: a qualitative investigation of the transtheoretical model. Soc Sci Med 61(2):293–303

    Article  PubMed  Google Scholar 

  30. Godtfredsen NS, Prescott E, Osler M, Vestbo J (2001) Predictors of smoking reduction and cessation in a cohort of Danish moderate and heavy smokers. Preventive Med 33(1):46–52

    Article  CAS  Google Scholar 

  31. Wu BJ, Chen HK, Lee SM (2013) Do atypical antipsychotics really enhance smoking reduction more than typical ones? The effects of antipsychotics on smoking reduction in patients with schizophrenia. J Clin Psychopharmacol 33(3):319–328

    Article  CAS  PubMed  Google Scholar 

  32. Cheng JJ, Ho H, Chang CJ, Lan SY, Hwu HG (1996) Positive and Negative Syndrome Scale (PANSS): establishment and reliability study of a Mandarin Chinese language version. Taiwan J Psychiatry 10:251–258

    Google Scholar 

  33. Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13(2):261–276

    Article  CAS  PubMed  Google Scholar 

  34. Simpson G, Kunz-Bartholini E (1968) Relationship of individual tolerance, behavior and phenothiazine produced extrapyramidal system disturbance. Dis Nerv Syst 29(4):269–274

    CAS  PubMed  Google Scholar 

  35. Huang CL, Lin HH, Wang HH (2006) The psychometric properties of the Chinese version of the Fagerstrom test for nicotine dependence. Addict Behav 31(12):2324–2327

    Article  PubMed  Google Scholar 

  36. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO (1991) The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 86(9):1119–1127

    Article  CAS  PubMed  Google Scholar 

  37. Gardner DM, Murphy AL, O’Donnell H, Centorrino F, Baldessarini RJ (2010) International consensus study of antipsychotic dosing. Am J Psychiatry 167(6):686–693

    Article  PubMed  Google Scholar 

  38. Chen HK, Lan TH, Wu BJ (2013) A double-blind randomized clinical trial of different doses of transdermal nicotine patch for smoking reduction and cessation in long-term hospitalized schizophrenic patients. Eur Arch Psychiatry Clin Neurosci 263(1):75–82

    Article  PubMed  Google Scholar 

  39. Ong KC, Cheong GN, Prabhakaran L, Earnest A (2005) Predictors of success in smoking cessation among hospitalized patients. Respirology 10(1):63–69

    Article  CAS  PubMed  Google Scholar 

  40. Evins AE, Mays VK, Rigotti NA, Tisdale T, Cather C, Goff DC (2001) A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia. Nicotine Tob Res 3(4):397–403

    Article  CAS  PubMed  Google Scholar 

  41. Lan TH, Chiu HJ, Wu BJ, Hung TH, Hu TM (2007) Readiness to quit and smoking reduction outcomes. Am J Psychiatry 164(5):827–828

    Article  PubMed  Google Scholar 

  42. Bohadana A, Nilsson F, Rasmussen T, Martinet Y (2000) Nicotine inhaler and nicotine patch as a combination therapy for smoking cessation: a randomized, double-blind, placebo-controlled trial. Arch Intern Med 160(20):3128–3134

    Article  CAS  PubMed  Google Scholar 

  43. Fredrickson PA, Hurt RD, Lee GM, Wingender L, Croghan IT, Lauger G, Gomez-Dahl L, Offord KP (1995) High dose transdermal nicotine therapy for heavy smokers: safety, tolerability and measurement of nicotine and cotinine levels. Psychopharmacology 122(3):215–222

    Article  CAS  PubMed  Google Scholar 

  44. Hurt RD, Dale LC, Fredrickson PA, Caldwell CC, Lee GA, Offord KP, Lauger GG, Marusic Z, Neese LW, Lundberg TG (1994) Nicotine patch therapy for smoking cessation combined with physician advice and nurse follow-up. One-year outcome and percentage of nicotine replacement [see comment]. JAMA 271(8):595–600

    Article  CAS  PubMed  Google Scholar 

  45. Evins AE, Culhane MA, Alpert JE, Pava J, Liese BS, Farabaugh A, Fava M (2008) A controlled trial of bupropion added to nicotine patch and behavioral therapy for smoking cessation in adults with unipolar depressive disorders. J Clin Psychopharmacol 28(6):660–666

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  46. Evins AE, Cather C, Deckersbach T, Freudenreich O, Culhane MA, Olm-Shipman CM, Henderson DC, Schoenfeld DA, Goff DC, Rigotti NA (2005) A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. J Clin Psychopharmacol 25(3):218–225

    Article  CAS  PubMed  Google Scholar 

  47. Liao DL, Yang JY, Lee SM, Chen H, Tsai SJ (2002) Smoking in chronic schizophrenic inpatients in taiwan. Neuropsychobiology 45(4):172–175

    Article  PubMed  Google Scholar 

  48. Addington J (1998) Group treatment for smoking cessation among persons with schizophrenia. Psychiatr Serv 49(7):925–928

    Article  CAS  PubMed  Google Scholar 

  49. McChargue DE, Gulliver SB, Hitsman B (2002) Would smokers with schizophrenia benefit from a more flexible approach to smoking treatment? Addiction 97(7):785–793

    Article  PubMed  Google Scholar 

  50. Oshima I, Mino Y, Inomata Y (2007) How many long-stay schizophrenia patients can be discharged in Japan? Psychiatry Clin Neurosci 61(1):71–77

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest. This supplement was not sponsored by outside commercial interests. It was funded by the Yuli Hospital, Ministry of Health and Welfare, Hualien, Taiwan.

Author information

Authors and Affiliations

  1. Department of Psychiatry, Yuli Hospital, Ministry of Health and Welfare, No. 448 Chung-Hua Road, Yuli Township, 981, Hualien County, Taiwan

    Kuan-Ju Chou, Hsing-Kang Chen & Bo-Jian Wu

  2. Ping-An Hospital, Pingtung County, Taiwan

    Chih-Hung Hung

  3. National Taiwan University Hospital Yun-Lin Branch, Taipei, Taiwan

    Tzu-Ting Chen

  4. Taipei Veterans General Hospital Yuli Branch, Taipei, Taiwan

    Chun-Ming Chen

Authors
  1. Kuan-Ju Chou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hsing-Kang Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chih-Hung Hung
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tzu-Ting Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Chun-Ming Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Bo-Jian Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bo-Jian Wu.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chou, KJ., Chen, HK., Hung, CH. et al. Readiness to quit as a predictor for outcomes of smoking-reduction programme with transdermal nicotine patch or bupropion in a sample of 308 patients with schizophrenia. Eur Arch Psychiatry Clin Neurosci 265, 249–257 (2015). https://doi.org/10.1007/s00406-014-0515-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00406-014-0515-7

Keywords

Search

Navigation